Please ensure Javascript is enabled for purposes of website accessibility

Celldex Therapeutics, Inc. Can Thank Pfizer and Allergan for Its Wednesday Bounce

By Brian Orelli, PhD - Apr 7, 2016 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a biotech thing.

Image source: Celldex Therapeutics.

What: On Wednesday, Celldex Therapeutics (CLDX 3.46%) jumped more than 11% on no news.

Or, at least, no company-specific news.

So what: Most of the biotech sector was up on Wednesday after Pfizer (PFE -0.15%) and Allergan (AGN) announced that their deal was dead in the water. Pfizer had plans to buy Allergan, in part to move its headquarters overseas to avoid U.S. taxes, but President Obama and the Treasury department changed the rules for tax inversions this week. Pfizer decided it was too risky to consummate the deal with the potential that it might still have to pay the high U.S. tax rate.

The result of the broken deal is that Pfizer now has incentive to do other deals. And Allergan could be a purchaser -- rather than an acquisition target -- after it ships off its generic drug business to Teva Pharmaceutical in exchange for $33.75 billion in cash and another $6.75 billion or so in shares of Teva.

Is either company interested in Celldex? There's no way to know. But, as we've previously discussed, Celldex's share price is currently at the mercy of the momentum traders that are more interested in the short-term news than the long-term potential. Wednesday's news was certainly good news for the sector even if Celldex doesn't benefit directly.

Now what: Current shareholders of Celldex Therapeutics aren't going to complain about a double-digit move higher, but keep in mind that momentum can work in the opposite direction, too.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
CLDX
$27.52 (3.46%) $0.92
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.